Acelyrin

Acelyrin shifts focus from izokibep to lonigutamab for thyroid eye disease, suspending further investments in izokibep despite positive trial results. The company cuts 43 jobs, aiming to extend cash runway to 2027 for lonigutamab's Phase 3 trials, amidst strategic restructuring.

Acelyrin, a California biotech, announced layoffs of 40 employees, a third of its workforce, following a pivot in priorities. Despite success in a late-stage trial for a skin disorder treatment, the drug didn't outperform competitors, leading to halted investment. The company will now focus on a thyroid eye disease treatment.

ACELYRIN, INC. announced positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, to be presented at the 2024 European Alliance of Associations for Rheumatology Congress. Izokibep, an IL-17A inhibitor, showed efficacy and safety in a study involving 351 patients across 71 sites.

Lonigutamab, a subcutaneous anti-IGF-1R, shows clinical promise in treating thyroid eye disease (TED), with Phase 1/2 trial data to be presented at ENDO 2024. It targets IGF-1R, offering potential for improved treatment depth and durability in TED patients.

ACELYRIN, INC. completed enrollment for izokibep Phase 3 trial in hidradenitis suppurativa, expects Phase 2b/3 trial in uveitis enrollment completion this month, with top-line data anticipated by end of 2024. Reported positive proof-of-concept for lonigutamab in thyroid eye disease and positive Phase 2b/3 data for izokibep in psoriatic arthritis. Cash and equivalents at $678.5M as of March 31, 2024. Leadership changes announced, including Mina Kim as CEO.

Acelyrin's lonigutamab shows promise in treating thyroid eye disease, matching Amgen’s Tepezza in severity improvement but with a lower response rate on eyeball protrusion. With no serious adverse events reported, Acelyrin plans further studies, aiming to compete in the TED market dominated by Tepezza.

ACELYRIN announced positive Phase 1/2 trial results for lonigutamab in thyroid eye disease, showing rapid improvements in proptosis, clinical activity scores, and diplopia with a favorable safety profile. A Phase 2b/3 trial is planned for 2024. Lonigutamab, a subcutaneous anti-IGF-1R antibody, demonstrated clinically meaningful responses early, supporting its potential for long-term treatment with minimized safety risks.

Acelyrin plans late-stage testing for lonigutamab, a drug for thyroid eye disease, after positive Phase 2b/3 trial results. The drug showed clinically meaningful responses and was well-tolerated. Competing with Tepezza, lonigutamab offers a quicker, subcutaneous injection. Acelyrin's shares rose following the announcement.

Acelyrin's experimental thyroid eye disease treatment showed symptom improvement in early-stage trial patients, potentially competing with Tepezza, the first approved medicine for the condition in 2020.

FDA approved Lenmeldy, a $4.25M gene therapy for MLD, the most expensive drug. Acelyrin reported positive results for a thyroid eye disease treatment. Clasp Therapeutics raised $150M for a cancer treatment targeting body's defenses with minimal risk to healthy cells.